BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsEarnings

Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs Net product revenues for the third quarter 2026 totaled approximately $323.8 million, consisting of approximately $240.3

Related news

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-10-22 12:30 EST

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

NTLAIntellia2026-11-05 13:00 EST

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

SANASana Biotechnology2026-11-05 21:05 EST

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

View all latest news

Sarepta Therapeutics

Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients...

Recent company news

SRPTSarepta Therapeutics2026-11-05 21:05 EST

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-10-26 20:30 EST

Sarepta Therapeutics to Present at Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-10-22 12:30 EST

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-10-14 12:30 EST

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

SRPTSarepta Therapeutics2026-09-30 20:30 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
17.57 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States